Special Issue "The Role of Host Cells in Tumor Progression, Metastasis, and Therapy Response"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 7361
Solid tumor microenvironment (TME) coevolves with the progressing tumor. Beside tumor cells, TME contains a variety of host cells, including cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), endothelial cells, and immune cells. Progressing tumor hijacks host cells to acquire invasive and metastatic properties and develop resistance to existing therapies. Tumor-educated host cells support tumor growth by secreting growth factors, promote tumor invasion by degrading the surrounding extracellular matrix, and facilitate metastasis by making the blood vessels leaky and escorting tumor cells into the blood. Host immune and inflammatory cells not only protect the tumor cells that are migrated into the blood circulation, but also help them seed into the secondary metastatic organs. Host cells, including CAFs, TAMs, and MDSCs have also been implicated in the development of immunosuppressive TME that support tumor growth and metastasis. Based on these pro-tumor functions, molecularly reprogramming the host cells to rather target tumor cells is being considered as an emerging therapeutic strategy. Recent clinical and pre-clinical studies using molecular checkpoint inhibitors have shown the possibility of reprogramming different immune cell types, including TAMs and T cells against tumor cells. However, tumor cells develop resistance to these therapies and other traditional therapies. Therefore, a better understanding of intricate molecular interactions between tumor and host cells is critical to design novel and efficient therapeutic strategies against solid tumors.
Dr. Dinesh Ahirwar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.